-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the country's centralized procurement of drugs (insulin special) selected list of officially announced, Humalog Eli Lilly's 25 ® and Humalog 50 ® to 73% of the price drop to get the premixed insulin analogue group A1 identity of the single price Only 18.
89 yuan
.
The patient's daily treatment cost is reduced to 1.
Recently, the country's centralized procurement of drugs (insulin special) selected list of officially announced, Humalog Eli Lilly's 25 ® ® and Humalog 50 ® ® with 73% of the price drop to get the premixed insulin analogue group A1 identity, single The price is only 18.
Eli Lilly is the only multinational company that has entered the A list of
The Central Purchasing price coincides with the discovery of insulin 100 anniversary, as the first successful commercial production of insulin, Eli Lilly and take concrete actions to offer " gift " insulin centuries
" As a leading global pharmaceutical company with a history of 145 years, Eli Lilly has always been an industry leader in pioneering therapies to improve the lives of people around the world.
Research continues to be committed to innovations in high-quality drugs and support services to meet the unsatisfied needs of patients.
Demand
.
” said Mr.
Ji Liwen, President and General Manager of Eli Lilly China, “ We are honored to actively cooperate with and support the government in this large-scale insulin purchase to help more Chinese diabetic patients use high-quality medicines.
This is also a gift.
the company has always been unremitting efforts to pursue the goal of
the future, Lilly will continue to uphold the ' rooted in China for the benefit of China ' concept, accelerate global innovation diabetes drugs into China for the benefit of Chinese patients, Lilly realized in the Chinese market and strong commitment to the field of diabetes treatment, is ' healthy China 2030' to make a real contribution
.
" in this message
